Jennison Associates
BEAM icon

Jennison Associates’s Beam Therapeutics BEAM Stock Holding History

Jennison Associates’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,359
Closed -$556K – 607
2022
Q2 		$556K Buy
+14,359
New +$571K ﹤0.01% 591

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates's BEAM Position: Q3 2022 in Review

Jennison Associates sold out of Beam Therapeutics (BEAM) in Q3 2022, closing a stake of 14,359 shares — an estimated $556K sold.

Jennison Associates first reported a position in BEAM in Q2 2022 and held it in 1 quarter. The position peaked at $556K in Q2 2022. 224 funds tracked by Wall St. Rank hold BEAM as of Q3 2022.

  • Jennison Associates reported no remaining Beam Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Jennison Associates sold 14,359 Beam Therapeutics shares in Q3 2022, an estimated $556K.
  • Jennison Associates first reported a position in Beam Therapeutics in Q2 2022 and held it in 1 quarter.
  • Jennison Associates's Beam Therapeutics position peaked at $556K in Q2 2022.
  • 224 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2022.

Based on Jennison Associates's 13F filing for Q3 2022, filed 1 Nov 2022.